94 related articles for article (PubMed ID: 30477719)
1. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
2. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
[TBL] [Abstract][Full Text] [Related]
3. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
4. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Natt NK; Gupta A; Singh G; Singh T
Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure.
Paul C
Indian J Ophthalmol; 2023 Dec; 71(12):3652-3657. PubMed ID: 37991299
[TBL] [Abstract][Full Text] [Related]
7. Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.
Konstas AG; Boboridis KG; Athanasopoulos GP; Haidich AB; Voudouragkaki IC; Pagkalidou E; Katsanos A; Katz LJ
Eye (Lond); 2023 Dec; 37(17):3666-3674. PubMed ID: 37221362
[TBL] [Abstract][Full Text] [Related]
8. Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study.
Le JT; Mohanty K; Bicket AK; Tarver ME; Eydelman M; Li T
Ophthalmol Glaucoma; 2019; 2(6):374-382. PubMed ID: 32455341
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension.
Hutnik C; Neima D; Ibrahim F; Scott R; Vaillancourt J; Haine D; Sampalis JS; Bastien N; Foucart S
Clin Ophthalmol; 2010 Jul; 4():581-90. PubMed ID: 20668720
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the effectiveness and safety of glaucoma drugs in the therapy of primary open-angle glaucoma].
Astakhov SY; Nechiporenko PA; Novikov DP; Frolov OA; Pokrovskiy AS
Vestn Oftalmol; 2023; 139(6):101-108. PubMed ID: 38235636
[TBL] [Abstract][Full Text] [Related]
11. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.
Rhee T; Kim J; Ha A
Korean J Ophthalmol; 2024 Apr; ():. PubMed ID: 38665112
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.
Cordeiro MF; Goldberg I; Schiffman R; Bernstein P; Bejanian M
Clin Ophthalmol; 2015; 9():1605-11. PubMed ID: 26357461
[TBL] [Abstract][Full Text] [Related]
13. Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling.
Le JT; Bicket AK; Janssen EM; Grover D; Radhakrishnan S; Vold S; Tarver ME; Eydelman M; Bridges JFP; Li T
Ophthalmol Glaucoma; 2019; 2(6):367-373. PubMed ID: 32355909
[TBL] [Abstract][Full Text] [Related]
14. Treatment choices for newly diagnosed primary open angle and ocular hypertension patients.
Garg A; Gazzard G
Eye (Lond); 2020 Jan; 34(1):60-71. PubMed ID: 31685971
[TBL] [Abstract][Full Text] [Related]
15. Prescription trends for preservative free glaucoma medication in a public health system.
Pérez-García P; Burgos-Blasco B; Morales-Fernández L; Fernández-Ruiz-Morón A; Gómez-Calleja V; Oribio-Quinto C; Collado-Vincueria I; Garcia-Feijoo J; Martinez-de-la-Casa JM
Eur J Ophthalmol; 2024 Jan; 34(1):193-203. PubMed ID: 37070183
[TBL] [Abstract][Full Text] [Related]
16. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
[No Abstract] [Full Text] [Related]
17. An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper.
Steger JS; Durai I; Odayappan A; Raman R; Sruthi T; Song AJ; Puthuran G; Venkatesh R; Colantuoni E; Robin AL
Ophthalmology; 2024 Mar; ():. PubMed ID: 38492865
[TBL] [Abstract][Full Text] [Related]
18. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
Bacharach J; Brubaker JW; Evans DG; Lu F; Odani-Kawabata N; Yamabe T; Wirta DL
Am J Ophthalmol; 2024 Feb; 263():23-34. PubMed ID: 38395329
[TBL] [Abstract][Full Text] [Related]
19. Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study.
Leshno A; De Moraes CG; Cioffi GA; Kass M; Gordon M; Liebmann JM
Ophthalmol Glaucoma; 2023; 6(6):592-598. PubMed ID: 37336266
[TBL] [Abstract][Full Text] [Related]
20. Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness.
Sharif NA
Exp Eye Res; 2023 Jul; 232():109444. PubMed ID: 36958427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
